drugset / Trial / NCT01879007

Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

NCT01879007

Phase 1 Completed 16 enrolled LG Life Sciences
RandomizedCrossoverOpen-labelTreatment

Summary

This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation (Gemifloxacin 320mg) and to explore possibility of clinical use of the IV formulation.

Timeline

Start
2006-01
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemifloxacin Small molecule 200 mg Intravenous
Subject Gemifloxacin Small molecule 320 mg Intravenous

Indications